Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

More Time for Bayer-Topsun Deal

publication date: Mar 5, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Topsun Science and Technology (SHA: 600771) has agreed to extend the deadline for the giant German pharmaceutical company Bayer AG (XE: 575200) to close its 1.26 billion RMB ($177 million) purchase of Topsun’s portfolio of OTC cold drugs. Bayer must now complete the purchase by June 30, 2008. When the acquisition had not closed in February 2008, Topsun announced Bayer was in danger of losing the deal, but a new agreement was signed on February 29, extending the deadline for four months. It is not clear what is keeping Bayer from completing the purchase. More details...

Stock Symbols:  (SHA: 600771) (XE: 575200)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Suzhou, China
May 18 - 19, 2016
Record attendance of 1008!
See us next year in Shunde!

>> More events...

Other Events
Hong Kong, China
June 15–17, 2016
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors